Shannon Thyme Klinger Sells 3,471 Shares of Moderna (NASDAQ:MRNA) Stock

Moderna, Inc. (NASDAQ:MRNA) insider Shannon Thyme Klinger sold 3,471 shares of Moderna stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $50.00, for a total value of $173,550.00. Following the transaction, the insider owned 67,468 shares in the company, valued at approximately $3,373,400. This represents a 4.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Moderna Stock Performance

MRNA stock opened at $47.73 on Wednesday. The business’s 50-day moving average price is $49.68 and its two-hundred day moving average price is $43.63. The company has a current ratio of 2.41, a quick ratio of 2.35 and a debt-to-equity ratio of 0.08. The firm has a market cap of $18.94 billion, a PE ratio of -5.86 and a beta of 1.05. Moderna, Inc. has a 1-year low of $22.28 and a 1-year high of $59.55.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Friday, May 1st. The company reported ($3.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.02) by ($0.38). Moderna had a negative net margin of 143.55% and a negative return on equity of 26.64%. The firm had revenue of $389.00 million during the quarter, compared to analyst estimates of $236.37 million. During the same period in the prior year, the business earned ($2.52) EPS. The business’s revenue for the quarter was up 260.2% compared to the same quarter last year. As a group, research analysts forecast that Moderna, Inc. will post -6.51 earnings per share for the current year.

Key Stories Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna and the University of Oxford received UK authorization to begin a Phase 1/2 study of the investigational mRNA-4194 cancer vaccine for people with Lynch syndrome, a high-risk inherited condition. The move highlights progress in Moderna’s oncology pipeline and could support long-term growth expectations. Article: Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome
• Positive Sentiment: Recent coverage around Oxford’s cancer vaccine trials and preventive mRNA approaches has increased investor focus on Moderna’s ability to expand beyond COVID vaccines into cancer prevention, which could be a meaningful future catalyst. Article: Oxford–Moderna Cancer Vaccine Trial To Test Preventive mRNA Approach In High-Risk Patients
• Neutral Sentiment: Moderna’s presentation at the Goldman Sachs Global Healthcare Conference may have offered updates on strategy and pipeline progress, but no major new financial guidance or product approval was highlighted in the headline alone. Article: Moderna, Inc. (MRNA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Reported short interest data showed no meaningful bearish positioning change, so it does not appear to be a major driver for the shares.
• Negative Sentiment: Insider Shannon Thyme Klinger sold 3,471 shares, which can weigh on sentiment even though the sale was tied to tax withholding under a pre-arranged 10b5-1 plan.
• Negative Sentiment: Bank of America raised its price target on Moderna but kept an underperform rating, reinforcing a cautious analyst outlook on the stock.

Analysts Set New Price Targets

MRNA has been the topic of several recent research reports. Evercore set a $35.00 price target on Moderna in a research note on Tuesday, February 17th. Sanford C. Bernstein reissued a “market perform” rating and issued a $45.00 price target on shares of Moderna in a research note on Tuesday, February 17th. UBS Group reissued a “neutral” rating on shares of Moderna in a research note on Tuesday, May 26th. Piper Sandler lifted their price target on Moderna from $63.00 to $69.00 and gave the company an “overweight” rating in a research note on Monday, February 23rd. Finally, Royal Bank Of Canada lifted their price target on Moderna from $35.00 to $38.00 and gave the company a “sector perform” rating in a research note on Monday, May 4th. Two analysts have rated the stock with a Buy rating, eleven have given a Hold rating and five have given a Sell rating to the company’s stock. According to data from MarketBeat, Moderna has a consensus rating of “Reduce” and an average target price of $36.60.

Institutional Trading of Moderna

A number of hedge funds and other institutional investors have recently modified their holdings of MRNA. AQR Capital Management LLC acquired a new stake in shares of Moderna in the first quarter valued at about $415,000. NewEdge Advisors LLC increased its position in shares of Moderna by 732.7% in the first quarter. NewEdge Advisors LLC now owns 11,575 shares of the company’s stock valued at $328,000 after acquiring an additional 10,185 shares during the last quarter. United Services Automobile Association acquired a new stake in shares of Moderna in the first quarter valued at about $230,000. Focus Partners Wealth increased its position in shares of Moderna by 58.7% in the first quarter. Focus Partners Wealth now owns 23,547 shares of the company’s stock valued at $668,000 after acquiring an additional 8,706 shares during the last quarter. Finally, American Century Companies Inc. increased its position in shares of Moderna by 5.2% in the second quarter. American Century Companies Inc. now owns 48,859 shares of the company’s stock valued at $1,348,000 after acquiring an additional 2,410 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.